Ginkgo Bioworks Inc.
Ginkgo Biosecurity is building next-generation biosecurity infrastructure to help detect, attribute, and deter biological threats. The role involves developing critical data systems and pipelines, applying cloud and AI technologies, and collaborating across teams to enhance biosecurity efforts globally.
Headquarters
Boston, Massachusetts, United States
Company Size
501-1000 employees
Founded
2009
Ginkgo Bioworks is a Boston-based biotechnology company that builds and provides autonomous lab solutions to accelerate biotech R&D. Its offerings include cloud lab services, lab automation hardware and software, and AI-driven tools (such as the Catalyst Agent) that enable scientists to run experiments using robotics rather than manual benchwork. Ginkgo also offers data and AI services — including antibody developability, perturbation response profiling, and specialized screening — trusted by over 130 customers worldwide.
Ginkgo Bioworks (NYSE: DNA) trades Biosecurity arm for 20% Tower stake
2 weeks ago
Ginkgo Bioworks Divests Biosecurity Unit, Retains Minority Stake
2 weeks ago
Ginkgo Bioworks and Givaudan Enter Multi-Program Collaboration to Produce a Series of Ingredients
Aug 30, 2021
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Ginkgo Bioworks Inc..
Sojitz Corporation and Ginkgo Bioworks Announce Plans to Use Synthetic Biology R&D Services to Accelerate Sustainable Manufacturing in Japan
May 15, 2024